Skip to main navigation

Careers    |    Contact    |    News    |       

  • About Arbutus
    • Overview
    • Management
    • Our Board
    • Scientific Advisory Board
    • Careers
  • About HBV
    • HBV Background
    • HBV Science
    • The Baruch S. Blumberg Institute
  • >
  • R&D Portfolio
    • HBV Assets
      • AB-729 (GalNAc-RNAi)
      • AB-836 (Capsid Inhibitor)
      • HBV RNA Destabilizers
    • Partnered Programs
      • Genevant
      • Gritstone
      • ONPATTRO™ (patisiran)
      • Marqibo ®
  • Partners
    • Partnering & Licensing
    • LNP Collaborations & Partners
    • HBV Collaborators & Partners
  • Investors
    • Investor Center
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Investor FAQ
    • Contact Us

Investor Relations

  • Investor Center
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Press Releases
  • Events & Presentations
  • Investor FAQ
  • Contact Us

SEC Filing Details

Document Details

Form
DEFA14A
Filing Date
Jan 26, 2015
Document Date
Jan 26, 2015
Form Description
Additional proxy soliciting materials - definitive
Filing Group
Proxy Filings
Company
Arbutus Biopharma Corporation
Issuer
Arbutus Biopharma Corp

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Shareholder Tools

  • Email Alerts Email Alerts
  • RSS News Feeds RSS News Feeds
  • Download Library Download Library

© 2021 Arbutus Biopharma

Legal Terms